Uncategorized Archives - Page 27 of 87 - PsychedelicNewsWire (PNW)

TuesdayAug 17, 2021 1:20 pm

New Poll Suggests 80% of Canadians Support Legalization of Psilocybin for Medical Use

A recent survey reported that four out of every five Canadians are in favor of the therapeutic use of psilocybin for individuals who suffer from a terminal condition; those respondents urge the government to establish a regulatory framework to allow its use in these circumstances. The poll was carried out by Nanos Research and commissioned by the Canadian Psychedelic Association (“CPA”). For the survey, more than 1,000 Canadian adults were interviewed between June 30, 2021, and July 5, 2021. More than 75% of the survey’s respondents stated that they supported the establishment of a legal regulatory model to facilitate the…

MondayAug 16, 2021 1:05 pm

Ibogaine May Combat Cravings, Withdrawal Symptoms in Addicts

While not many effective treatments for substance addiction exist, approximately 22 million people in America are on their way to recovery. Unfortunately, recovered addicts constantly stare the risk of relapse in the face, and a number of medications to curb withdrawal symptoms and cravings are being considered. Ibogaine, a psychedelic substance found in the iboga plant, has grown in popularity due to its ability to help combat addiction. Ibogaine has its roots in West Africa, where it is harvested from a shrub called Tabernanthe iboga. The indigenous people have used it in small doses for millennia to combat thirst, hunger…

FridayAug 13, 2021 10:45 am

What We Should Know About Psychedelic-Assisted Therapy

Research on psychedelic-assisted therapy has demonstrated the many benefits the treatment approach has. With more investors becoming receptive to the use of this approach as an alternative treatment in the future, some biopharmaceutical companies that aim to make psychedelic drugs to treat various mental health conditions have launched their IPOs. The companies in question include Compass Pathways, MindMed and Atai Life Sciences; the companies went public in November 2020, April 2021 and June 2021 respectively. Together, these firms have more than nine psychedelic therapy medications in their product pipelines. So how do psychedelic drugs work for therapy? Psychedelics are known…

FridayAug 13, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Insights on the Psychedelics Space on The Dealmaker Podcast

Mr. Greg McKee, CEO of Tryp Therapeutics, appeared on The Dealmaker Podcast to share insights on the company and the psychedelics industry During the interview, he discussed the potential of psychedelics in the treatment of PTSD and other mental disorders Greg also shared the challenges that the industry is facing currently, mostly to do with legislation McKee also shared how people can help the company and the industry by pushing for the decriminalization of psychedelics and taking part in clinical trials On August 2, 2021, the Dealmaker Podcast posted an interview with Greg McKee, the Chief Executive Officer (“CEO”) of…

ThursdayAug 12, 2021 1:45 pm

Psychedelic Decrim Efforts Advance in Three Cities Across the US

Psychedelic reform advocates in various states across the country are actively working to change laws that govern psychedelics, including ayahuasca and psilocybin. As part of those efforts, cities such as Arcata, California; Grand Rapids, Michigan; and Easthampton, Massachusetts, are the latest to climb aboard this reform train. Thus far, the Public Safety Committee in the city of Arcata has advanced a psychedelics reform measure that was led by the Decriminalize Nature chapter in the city. This measure will allow the decriminalization of entheogens, which had been denied by the Arcata City Council, to be voted on again. The passage of…

WednesdayAug 11, 2021 2:15 pm

First Global Psychedelics Research Institute Opens

A first-of-a-kind global research institute aimed at developing psychedelic medicines and related therapies targeting mental health conditions has been launched in Australia. The network of researchers has so far secured planned investments amounting to AUD$40 million ($29.5 million) expected to be availed over the coming five years. Psychae Institute, as the research institute is called, is the first global network through which leading psychedelics researchers will collaborate. The team includes members from King’s College London, University of Zurich, University of Toronto and the Federal University found in Rio Grande, Brazil. The Australia-based institutions that will participate in this collaboration include…

TuesdayAug 10, 2021 1:00 pm

Study Finds That Psilocybin May Change How the Human Brain Processes Tactile Sensations

Psilocybin is the active compound found in psychedelic mushrooms that induces psychological effects, mainly through the serotonin receptors. A study that was recently conducted has found a way to explain how psilocybin changes how the human brain processes mental representations and tactile sensations of an individual's body. While most of the underlying neurocognitive processes of these changes in an individual’s perception of self are unclear, it is known that the psychedelic substance causes alterations in body/self boundaries. Katrin Peller of the University of Zurich, who is the study's author, stated that research focused on psilocybin, among other psychedelic substances as…

MondayAug 09, 2021 2:30 pm

MDMA-Assisted Therapy May Be Effective in Treating PTSD in Couples

Post-traumatic stress disorder, commonly referred to as PTSD, is a mental health condition that is usually triggered by a petrifying event that one witnesses or experiences. The most common symptoms of the disorder include severe anxiety, upsetting dreams or nightmares, and flashbacks. Other symptoms include severe physical reactions or emotional distress in response to a situation that makes an individual recall the traumatic event or recurrent distressing memories of the event. Estimates show that post-traumatic stress disorder affects about seven million individuals in the United States. This disorder has been linked to various conditions, including anxiety and depression, as well…

FridayAug 06, 2021 1:00 pm

Oregon Board Concludes That Psilocybin Is Effective for Various Mental Health Diseases

A panel created in the state of Oregon under the psilocybin legalization measure that was approved by voters last year has submitted a report stating that psilocybin possesses significant medical benefits for various health conditions. The Oregon Psilocybin Advisory Board subcommittee reviewed nearly 600 studies on psilocybin and came to the conclusion that the psychedelic had demonstrated effectiveness in decreasing anxiety and depression, even in fatal conditions. The panel asserted that all the studies they reviewed used a clinically supervised setting. Their report, which was compiled after eight weeks of review, stated that psilocybin was found to increase spiritual well-being…

ThursdayAug 05, 2021 1:23 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present Flagship PFN Program at 2021 Canaccord Genuity Virtual Growth Conference

The company will present an overview of business operations and its pipeline, including the Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders The initial indication of lead drug candidate TRP-8802 is for fibromyalgia, but Tryp believes that psilocybin can be used for much more in the realm of unmet medical needs PFN’s development for its proprietary drug candidate, TRP-8803, focuses on increased efficacy, natural blood-brain barrier penetration, enhanced safety and toxicity profiles, reduced risk of abuse, and reduced risk of addiction Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a San Diego-based pharmaceuticals company, has joined the lineup of presenters…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized